<SEC-DOCUMENT>0001571049-14-004549.txt : 20140911
<SEC-HEADER>0001571049-14-004549.hdr.sgml : 20140911
<ACCEPTANCE-DATETIME>20140911163833
ACCESSION NUMBER:		0001571049-14-004549
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140910
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140911
DATE AS OF CHANGE:		20140911

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		141098497

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1401764_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): September 10, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>Delaware</b></font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>0-50626</b></font></td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>91-1707622</b></font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(State or other jurisdiction</b></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(Commission File Number)</b></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(IRS Employer</b></font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>of incorporation)</b></font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>Identification No.)</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Berkeley Heights, NJ 07922 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices
and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective September 10, 2014, the Board of Directors
(the &ldquo;<B>Board</B>&rdquo;) of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;) appointed Samuel L. Barker,
Ph.D., to serve as a Class 1 Director until the 2016 annual meeting of the Company&rsquo;s stockholders. A press release reflecting
Dr. Barker&rsquo;s appointment, dated September 11, 2014, is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no arrangements or understandings
between Dr. Barker and any other person pursuant to which Dr. Barker was appointed as a director. There are no transactions to
which the Company is a party and in which Dr. Barker has a material interest that is required to be disclosed under Item 404(a)
of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Barker has not previously held any positions
with the Company and has no family relations with any directors or executive officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 10, 2014, the Board granted,
under and pursuant to the terms of the 2006 Equity Incentive Plan, as amended, to Dr. Barker an option to purchase up to 9,000
shares of the Company&rsquo;s common stock, at an exercise price of $3.26 per share, for his services as a non-executive director
of the Company, all of such options to vest on the first anniversary of the date of grant. The option expires on September 10,
2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, Dr. Barker is entitled to receive
an annual fee of $45,000 for his services as a non-executive director of the Company. Dr. Barker will also be reimbursed for certain
customary business expenses in connection with attending the Board meeting. Dr. Barker will also serve as a member of the Audit
Committee and Compensation Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dr. Barker has been a director since September
2014. In 2001, Dr. Barker co-founded Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical
companies, and served as its president and chief executive officer from 2003 to 2004. Dr. Barker served in a series of leadership
positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service
as executive vice president, Worldwide Franchise Management and Strategy during 1998; president, United States Pharmaceuticals
from 1992 to 1998; and president, Bristol-Myers Squibb Intercontinental Commercial Operations from 1989 to 1991. Prior to 1989,
Dr. Barker held executive positions in research and development, manufacturing, business development and operations planning at
Squibb Pharmaceuticals. Dr. Barker has served as a director Lexicon Pharmaceuticals, Inc. since March 2000 and served as chairman
from 2005 to 2012. Dr. Barker also served as a director of Cadence Pharmaceuticals, Inc. from 2006 to 2014 and of AtheroGenics,
Inc. from 2005 to 2009. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and
his Ph.D. from Purdue University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 10, 2014, the Board of the
Company declared a quarterly cash dividend in the amount of $0.15 per share on the Company&rsquo;s 6% Convertible Exchangeable
Preferred Stock (&ldquo;<B>Preferred Stock</B>&rdquo;). The cash dividend will be payable on November 1, 2014 to the holders of
record of the Preferred Stock as of the close of business on October 1, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board considered numerous factors in
determining whether to declare the quarterly dividend, including the requisite financial analysis and determination of a surplus.
While the Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future
quarterly dividends will be declared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>Exhibit</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>Number</B></FONT></P></td>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="width: 88%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></td></tr>
<tr>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt">&nbsp;</td>
    <TD STYLE="font-size: 10pt">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; font-size: 10pt"><font style="font-size: 10pt">99.1</font></td>
    <TD>&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font-size: 10pt">Press Release, dated September 11, 2014.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td colspan="2" style="font-size: 10pt"><font style="font-size: 10pt"><b>CYCLACEL PHARMACEUTICALS, INC.</b></font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</td>
    <TD STYLE="width: 6%; font-size: 10pt"><font style="font-size: 10pt">By: </font></td>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid; font-size: 10pt"><font style="font-size: 10pt">/s/ Paul McBarron</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font-size: 10pt">Name:</font></td>
    <TD STYLE="font-size: 10pt"><font style="font-size: 10pt">Paul McBarron</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="font-size: 10pt"><font style="font-size: 10pt">Title:</font></td>
    <TD STYLE="font-size: 10pt"><font style="font-size: 10pt">Executive Vice President&mdash;Finance, </font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer and Chief Operating Officer</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 11, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%; border-bottom: black 1pt solid; font-size: 10pt; text-align: left; vertical-align: bottom"><FONT STYLE="font-size: 8pt"><B>Exhibit
    No.</B></FONT></td>
    <TD STYLE="width: 2%; text-align: left; vertical-align: bottom"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></td>
    <TD NOWRAP STYLE="width: 88%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top; font-size: 10pt"><font style="font-size: 10pt">99.1 </font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: top; font-size: 10pt"><font style="font-size: 10pt">Press Release, dated September 11, 2014.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1401764_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 70%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><img src="logo.jpg"></FONT></TD>
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="logo1.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS APPOINTS SAMUEL
L. BARKER, PH.D., TO BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Berkeley Heights, NJ, September 11, 2014</B> - Cyclacel
Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) (&ldquo;Cyclacel&rdquo; or the &ldquo;Company&rdquo;) announced today the
appointment of Samuel L. Barker, Ph.D., to its Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are very pleased to have Dr. Sam Barker join the Board
of Directors of Cyclacel. His strategic outlook and experience in marketing and commercialization of novel therapeutics further
adds to the strength of our Board,&rdquo; said David U&rsquo;Prichard, Ph.D, Chairman of the Board of Cyclacel. &ldquo;Sam&rsquo;s
experience as a senior business leader in the global pharmaceutical industry will be very valuable as we advance our business strategy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Barker has more than 40 years of experience in senior executive
positions in the pharmaceutical industry where he played a significant role in the commercialization and success of several important
pharmaceuticals including Taxol<SUP>&reg;</SUP>, Capoten<SUP>&reg;</SUP>, Glucophage<SUP>&reg;</SUP> and Pravachol<SUP>&reg;</SUP>.
His previous roles include co-founder of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical
companies, serving as its President and Chief Executive Officer from 2003 to 2004. Previously, Dr. Barker spent over 30 years
at Bristol-Myers Squibb Company where he held positions in research and development, manufacturing, business development, sales
and marketing, operations planning and general management. After the merger of Bristol-Myers and Squibb in 1989, he served as
the President of Intercontinental Commercial Operations at Bristol-Myers Squibb Pharmaceutical Group. From 1992 to 1998, he served
as President of the United States Pharmaceuticals Group and from 1998 until retiring in May 1999, he served as Executive President,
Worldwide Franchise Management and Strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We welcome Dr. Sam Barker, a highly regarded figure in
our industry, to our Board as an independent director,&rdquo; said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.
&ldquo;In addition to his extensive business experience in drug development and commercialization, Sam adds high-level transaction
expertise to our Board. We look forward to working with him in realizing the value of Cyclacel&rsquo;s pipeline.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&ldquo;I am excited to join Cyclacel&rsquo;s
Board of Directors at an important moment in the Company&rsquo;s history,&rdquo; said Samuel L. Barker, Ph.D. &ldquo;Cyclacel&rsquo;s
pipeline includes the late stage program around sapacitabine in hematological malignancies and multiple oncology programs around
the Company&rsquo;s kinase inhibitor portfolio, including CDK inhibitors, a class with rising visibility in the pharmaceutical
industry.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Barker currently serves on the Board of Directors of Lexicon
Pharmaceuticals, Inc., a public biotechnology company and served as chairman from 2005-2012. He received his B.S. in Biology from
Henderson State College, his M.S. in Health Physics from the University of Arkansas and his Ph.D. in Radiobiology from Purdue University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel is a biopharmaceutical company
developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.
Sapacitabine, Cyclacel&rsquo;s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an
SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer and in particular those carrying gBRCA mutations. Cyclacel&rsquo;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Wingdings">&thorn;</FONT></TD><TD><FONT STYLE="font: 8pt Times New Roman, Times, Serif">200
                                         Connell Drive, Suite 1500, Berkeley Heights, NJ&nbsp; 07922 USA T: +1 (908) 517 7330
                                         F: +1 (866) 271 3466</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.45pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Dundee
                                         Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382
                                         206 067</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><U>www.cyclacel.com
</U>&ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel&rsquo;s product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;potential,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;intends,&rdquo; &ldquo;continues,&rdquo; &ldquo;forecast,&rdquo; &ldquo;designed,&rdquo; &ldquo;goal,&rdquo; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company: Paul McBarron, (908) 517-7330,
<U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations: Russo Partners LLC,
Robert Flamm, (212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&copy; Copyright 2014 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel<SUP>&reg;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```&XP``%Z(``!\]```G,O_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`1`"U`P$1
M``(1`0,1`?_$`08``0`"`P$!`0$````````````'"`4&"00#`@$!`0`"`P$!
M`0`````````````$!0,&!P((`1```00"`0(&`@$%`0``````!`(#!08!!P!`
M$Q$2%!46"#`7$"$Q(R0U-Q$``00`!`,&`P4%!@<``````P$"!`4`$1(&(1,4
M,4$B,A4'46$C$$!")!:!4F(S0W%S-#5U"#!RDF.TM282``$!!`8%!P@(!@,`
M``````$"`!$#!"$Q81(3!4!!47$B@9&AL3)2%/#!0F*2(Q4&T>%R@J+",T/Q
MLM(D-#5CDU03`0$``@(!`P0#`0$!`0````$1`"$Q05%`87'P@9&A$+'1P3#A
M\?_:``P#`0`"$0,1```![^&JV-3SK[=\VQI?:OBI$3+1IG0;BWT58+3.B@``
M````#5+&HY@]_P#E?98%IJMC4ZA9TV;B3O1CRVM^:OL2YOY[```````YZ]J^
M<O1XR:]-K](MJ+R9,.RUUOKG&OH2Q]/L-U```````8TI/UW@>DVU)N-7=2YK
M6X>;UYU?5MUFJLNI:*D&)+6$,D+$SEB2M9/97<^A!I84GTJ@:MUO@OV\YI'H
M]DLQH74-0-O!'14`OB<-B<CJZ<YCI,<M3;#!'0XXN$_'5(%9]\Y?C)$3;ZRY
ME'7]K]./+FHL[T>,GC.7Y=`@TDT@LU8EPB4]AX"PI1\E$L:6\(&W#G^2P2O/
M[Q?;SD_+SLD&SW2JO,G@E````````0!N7/,Q&FYV'/\`Z8S/%_/ZE[6MQ```
M`````%?]SYWH=Q0?E^>+-'N)S'M'W\9```````!__]H`"`$!``$%`N3,W%P`
M,_NR8D'EPVW;'Q5-VA#JC-JWJO$4[8\%;\=!-S(-?BQH^Q[=F$V@.+(E("U/
M\&K3Z%GV&RQ>1-<%2[](WMKR^67\^QW3+E<K2V[)R#.'7TA0M8<S*1,0.W7X
M613R7L=LK4S2-!Z]U_:OS>L$\-8]L^6B<FCT8^*CAFQJ2]+L$Z\9C$LPCLH5
M2J17-?0?+-NJEUR97NZ!8KT=*Q\K%UG9U6M,"G[!U4WA&SJX,=S9.UJIJL./
M/$E0+=M^F4Z4K.TXNR/1WV1K$P'+;-@(0LEGU`_ZW,\^L`W?UU$L^>JLBIR;
MR5A0YMO^+?)$0U3^LT''Q^J30Q9$-QB\5@S=-?C(X,<<<1C;?_L?!A8S:NX]
M`3I8-/\`JT(P?2I[_A:#V+=8#5VZG7']C?Q4$XB+1&QCN8KO,%MLR"FV\R+:
M^-NMN_P0PR4Q!5C;6E<T>>O$\F7J5A(^PFV-;M[*K@MR^P40QM**V0;.1MZV
MS)!4+ZV4)%2AM7$:SW$'2]F:?FH&>V1:&=5R.[-:TC<$/L*>D*;==DSDWRX@
ME"O&M>],!NHE'$/BA\S(`D8!4<U@,P<\;H2(N3JI;7QNW\2Q:A>*^7.\57V,
M\"LKDT?T5J^&>J1^P>/?MORL_%O6-]OM]!__V@`(`0(``04"X**08Z'5!64X
M*K0/,2E?*P_78@U$G!EQG0B"NFD+>!K0V8]PA`YD<CBSTYPR$`1QV=;&1G^_
MYX-+47%Q^4CLJ\J>.E2&.#DDKR>:,E)IY,@]T$_XLC$]I<NR0\O+DJD929O+
MW"2R"\]#/NI][(5X2*G/\722?^S'OOI]1Y5-Y4SYL]C..93E/11;K;B6E>E4
MZG(^,H<=YV74<=PTKCC:V5]"@AB0;5ZZ,YE<<YS'MJ>8-7QT#`K/11WNG;S[
M+Q/QOQ5[AVE>/CT'_]H`"`$#``$%`N&G"Q[$A>32%Y"N,ES,+:@LBVV>CG(6
MR@3..@.-8CA6AY*XF8E617"X^6<XW&+QDB1DQ>,5EXUS'],?GLRWIJ:E4K*(
M1A2\,`Q2N%!AMIBXXQ:XV,#B6.@JWE(,#[[<"^*,TEJ#68A=;2/P(`4%/0U5
ME7QL5'C%(:QW^DAL8#E1159$\Z'DH(RE/J4YXE25=%-,.M+?1ZY#*L%*PXTS
MS)##G&,OHXR\V0UT+@I42\CVV8YAN6:YGWA7,QS?&9-1Q'12WLG=Q\BXOYAX
M(]J[R?+Y>@__V@`(`0("!C\"80)9)5$+8N8KO'8*$CEK/0SD&"#8+W32UU2X
M3O62[K#7X'`_6@T<U37U<<MWAY]F@IEH`?$46$M`&)/+U:U':;-@_BWCOF2-
M=A:H;W`?78*;6=E<G$B)[P0X>TIG3LC&$/["5CH;Q.1Q<&-ZO9W+AEE2N<0[
MLS=J%*5BS?;H,3.8PXU4)\K5=`9?S)F?''4?=C:;.H;`&3F&<@QI^)^E`&H:
MJ/+E+#QTU!DT]Q(O*`9TC/PHZ^[$2Y_**65'C),IG<,4.]/EJ4DVU-C3)>MS
MM!E,I1J0"=]7TM"D5?X,E"O$?9#_`*&\?1\2FE$()JA0D]I7T;BQ3ER1;%6+
MT1=M/9W-<S.&B-#V@!*Q:%!@8ZU*"0X/V:%`C?MW89Y+SVS)/IF$KK3YF2[_
M`,+A[?%T/T65GA6$X2MZ:N<-!S0TP(T.[$WNN+'-Q!O"T&-#+X>Q:%:N6L;R
M*V]US&L,^(0E/EJ:G0EY9,%T"-4>[$'9.XU%HF6Y@"()-.U"A4L>?O)Y&$M.
M\4O^W$3^4ZT[4FJPM084<;W*Z2E76S[D&':I0/63U-<051II1[5+N05GEYF,
M.)0L:$)>>-R92'(BV=V)9L5JUM@QD@RZM1XD*M2?.DO9Y1$AFPA0YBX_B:G&
M5[*?ZFP<OAX=ZBCB6?O5^R`Q5.JNS)[,,4JWK[HL[6AG`_P]=]V%^*CFI;^[
MPL3_`(<1W31S4-1>?ZUYWX:6/PK`PM>!V^5_O&XNUH/_V@`(`0,"!C\"8S,X
ML(A#R<-I;!RB'<3J)%Y9W)J'2SX@F2#WC<'-0U]"(X/J*?\`REL.:.(!6F('
M'GH/6V&CW<WW#^4^EUV:"N<F2Z$@>0%I94[-*PLL1KU)&Q.U7>/\&^&_*$O?
MC:XKKRC:++3PV,_.\PA0E=U40D^RFAGY=F4`QMF(J&>EA)_,L#'ES5>[6^'%
M'ULB=R"*%2=ZM1NKAD:E;2+*VIKT"#\O2Y="3Q+ZW_=35:6A_*&3<$LA+XIV
M"WK/>)`9>5?+I$OE<+]:9-:CKXOHZ!6?ALE,9@H5Q%DH039];7LSRN/+0^_"
M65.Y"]+(EI=29[Y;C&E_[?(>)"Q96WAI-+H;W[23H,_GL3THA`/JBD]%UHV9
M(_V691[J3K%Y5T?FZ&^&./PB10DQ`*XT9791RUG>&"\W6JJB##-R%#'=X77C
MM);$R>-$EXNPDKAJL4E3V4)9"4%9>J[43YMVA3,O^]?BIY;H#9.OT!'2_P!E
M?G95ZKXF\_\`6+G3=T6>RPU%>,C[*Z^8T-,9(FB9EXM^%N*L2$=UYZ#N;QU(
MEXH`BC7"B(J5]TT*W)-3V]_[0I2;:*MW6SH0*U>59+<)!T*'G,H+TS+]I(K7
M"/:3O':3:T+-\J4#,)3P[(B#7#5LL[JN5C.9<;DW5%A+V[%CT5;%AX([P<W$
MF-+*V`7D<C@I/\NYKIB3$:Q*2.E*4]*G-B1`B7DD#LT/WJ/93N#[2PC02^&J
MHZ$J:RQ.))K+XD'6_6N%;M14=5+>(EEE,VC6GABIL4/RJ!#.$2#%3ZP*%<Z7
MC\(9P\,CVU]'`V/FL4Q@FGB<F$+;E7ME3!&7(OR0/%%-"=T/OFWLC;H8\5_L
M/1PGXW)<XN>AO['&P=6/A/Z.+GI;BN.=Z%Q_XZ&'QSQ./J\3^F^R[[EA<=<T
M'__:``@!`0$&/P+!+&VECAQ1\-3_`#$?^$01MS>8KNYK45<+#VI`Z-CG:!23
MAZRR-QX.%$;K`'4G<J$7&J2'<16/35E,D)7A_=X!(6,QO_2F.>&#>,>B+]2N
MG]2]$3M_PLE[\=-9D=8-&N1(5U&44E$3@N1VL#*:[A^+6GRP@!.6!;(W42KE
M.;S'9>9T0O!DH:?+)R=[?N,NVL2<N+#'K=EQ>1R^$81-_&4SU1K4^.#W%G(]
M+VY!>]%.]?RL&.SQNCPVO5!EE\OB4J\$[^YN';<]I=O)-F9*,]^2.LV9(5.#
MRA5Z(B!_[A%:+X,PY^\]_P!95%<BJL&9=%D';^+0M?7Y!'EGV)A';>]Q:(\S
M/@%EM/ISO5/$B#?)1@R?M5$P.H]QJ+UVO?\`RB6`V-L&L7^O4WL;@1R=OF=G
MWY8AW>Q;4<BF=(:]LJ:?H[.B.%[7O%,8U/J%C)Q1P_,GRXXF;0H+*8>WA#.X
M99,%T:);,AY-E&K3:W*1!^;)[1JK>+45/N%/L"O(K(T91S+4C>*#>\?->5_<
MO1P7>%.\A<L5OM+L_P#(UL..(FX)0_$T,;PDY9U33S%\2/)QS*5[4^.)NV/;
M\@J#;-3FW<^]SN1II9A-^NC)?@<[++\"I\E8SM(FW-F[AW^5COJWEA*-6U9S
MZLG.%ERN:Q5_>\6'/W+[8W6VXRKXK6AL23!1DR\Y`&0L3)%7/BK<\1HL:?"W
MA[9V"N=8%G%8!E$$37$.<XY!62*:="&FK-BZ')C8M7[(;>KMW^W]]+<[<%Y$
M<Z\$::Z=TMA&EVT>5R*IL&N"CD(3PJJY<=.2SMW[?B3VV<ILH<8<J:IX=4*:
MJ+)'7AY;'-UHFE%(XBM8N2?\?/JH^299KSAY<55J<=67%R9?VXWWO<ZZN?82
M(T8J^5(@OS1=*NSR3E()/EIQ<;C`B_J/W$O?3X1L_J"%837Q`M:[S,03.:Y,
MOX<)MG01^TME0X4BWC1_";<^Y9^ET"L(YO$G-(]KWM_>(U%X99"-NR9)XL3D
M;;IY1*VBJ1=K(B-@N"2>43>#B.=I5>Q,LL.E[3N9VWI+/,"5+/8T<D;E36"=
M`FE(BC>G#-JHJ8?6[;@5E3M);;<-+[EUEK1VD&1N)2580-+MHI'-;Z:XDE<B
ML5!JGE5=*I@>W-K0G0:L<B1*Y1),B65\B4Y'&*0\DA"O<NE$[<D1$3[#;;#Z
MUNG<L9N<JAV=3RK^?#S5J:9JQM,2(3-Z9M>1'-[T3%YN.?MC?M6';3H'K<"T
MVP6#91(U@4H1SF!/(:"9#"07U7!(3EHN:IEB'=0)89%7/A!L(LQKTY)(9PH<
M9]2\&M43LUS[,76ZHACP-L4DV;#)?W#`P*R:VN=HE3Z\[SNYU<U_A0JHW4[P
MHF:*F''H-L>XVZ*EBNUWU!LNQE5&ECU&X@C'6*:0Q'M_IC=C8->\=KS_`'':
M=U!J@.!RTCQ!3"):"DO#(@$01D32K%<CN"HGV5LS<[I[O5I)X\.-616S);TB
MAY\N0H7&!E&BC5-;L^&I,0K.`9LB#8Q(\Z&=GE-&E"8<!6_)XGHN&;?E&LKG
M<I`]0W;>V*N5>W*!TZD>:-#:K(J.;Q3FO8JHN?9QQ91'[<WKMN;5U9[@\3=&
MW)%2XD&,H4(^+(4AH<@F9V^!":L#L*C9/NG:P"J]!3:[99YD0JC<K"(.1'EO
M$_0]JHN2\%3'M_!LHMS'E^XYFQZ2.2`C#1#J*"5P;@9#L?!*+U!C7-R>K7([
MX8.#6X7/"4/,9P>/F,5FMG\3,\TPI/57Y]6V3R><_I,NI=(Z+D\OA2IG_A_-
MJ_'EPQN.`C=,M9FX8A&9\6R>@$!&K\%1<L>T)6_R`7->I=62>,D&S8/AW_F5
MX8D\QB9+[D(>3K3+4C:82UZ]GB1#\G3\_L=#M&I,JC`>&74'$`D*8[GQI`#'
MU"61S(KX_@1KT;XES15RR^S=%O$T]75;=N[*+J3-O40:V3)#J3O;S!)BCNPZ
M)%ONQ\^]O[5V3Y<^P-8RQJD@_%[NE8)&99Y(]'+VN7$JOG`'*A38YHDN,5-0
MCQI`W",$C>]A!N5%Q8?[7ZATCHMS6'6;9W6\V9*?VSLEE2=Q1W9^,DN$X!8[
M.S6I']F8\>QGM+"1(&S+C>==5V41KU9UL"IZ1PX9R)IYCIYY2N>[M<?)W;@,
M6*$4:-'&P((X!M$$(1M1HQ"&Q$8,;&IDB)P3'^WO_6]T_P#JXWV;ZFVQ`%VM
ML&@D^WE:(KP\N1=WX"IN>6+4J_4BQU6.J_\`+EC<NQ+-_67GM3;6="J(YJNF
MU`U/*HI`]&KZ1@-<-G\(TQ;;[F-ZC=&\]SWLR\L3Y/E.Z>:\((2/\PXH<E<@
M^Q%?\,L77^DV/_AFQ05E1[0[FW5``6V4%W7V=;'B2N;:2R$08I#5*WD$<K%^
M;<?[:#E`^*4V[IQ21B*CB1R$3;CW@>YOA5XG+I7+AP^W>VVW^%AIPMRU[%3P
MDB6HVLE:$7M0$L>E<7^S&/:*RV]9^J4#R<$6*69ZQ1G^8ARFOCDR[-"IAUUI
M**!:!%'O1)PE4=M6.TAF/;EJ1T,K>6;X<L;^+,\-ZYN7!NF9'8XT.4UV2,*-
MPN8HE)GY7?L5R<<*R*(TLJ.T*U@WC&Q?B4Y6L&QJ?M7X(N'*,C":7N&[0Y'Z
M2-\S%R['-7M3[#19(VFCR1$`<+TS84)F*,HWIWM>QRHN+"EV725WN1[>$F'G
MTE7(NA4FY=O]652R(##S&+#F14(Y53O<[-W@551;$V\-D#V4(;HZ54=;Z'=S
M);7<[JGR^B&T,3E9#TIF[5FN-J;R#6O?MJOV)95,RTYT9!AL#2;%XHR@4R2G
M*YIF\48K>/;@5>&>ZFOZ>PCWFV+MB*YU9<PLU`]Z-\:QRYZ7Y<4X.3-6HF!5
MMQ[256Y[$8D'Z_1[QK:VKFO9X.I/#G!ZJ(I<M2HUO:O!K>S'LSO2IV0E[;;5
M=;3]Q45?=5\<$2980(0%B!L9Y`H8;"Z])&L7/1V)GC<?7>T$O;TN'MVPF4+W
M[FI+1+.^;RA5]9R@O"@6E<52.(]R-1HU[U3%,_?VU8UQO.6!]AN.=*GV#C.L
M[`Q)AP.6'.'&=TG.Y6;4R<K<\USSQ46WM]MUP=@[EV[)I]V1HTQK@U%C$*Z3
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MA?Q-^>*O=NUS@-8`CJ^(JOT1K>M/D^143'IFHM3VYL<O\@[>*>;!K?;Y&PK7
MP"O:*Q1PT>9C=/*L0,S)#G#:F0Y+$<TC$_J-RR7F`N=N$XN($,=\VK5ZN\3A
M*`$Z`U'.=W()R]Z8T.L;ZX5%RZ:!`D`:7//P/+#A1&:.''45K?CA)$D,/;]+
M#$16P7.`XRMR7ZTV0QW1PA#\VABO7/S/[L"F1"<V,=NL)=+V(1F:IK:A&M=I
M7+@N7%./W*1:;;C.L*>89\FVVR-6L*,[^);*A5RHQIB+Q)&7)I%XMR=AMA7R
MR1[6(G+=)AD=7WE>O?%GQWMYFA'=HI`WC7X8TLGU-J-,\EFQ3UTM?@A#0G'C
M*OS0#?[,9,;MZ#\2*2QLER7O:+EUJ:F_-W''7;HMB6[8R\_ES.3`HHJLXH7T
MYBH!_+[G2'F5OQP$.WX75TXB+ZA?'U@@.:UKDZ>H32C[$RORS(WZ#4[U7[F+
MU/5Z_I_)^A]5^I<N&7*]+_.<O^\^EA?1/6>DX<K]6>@=1^WIOS>C^\\>'\SH
M]&A?\J]*ZK//^GZC]'5EV8#^M?U+UVMO3_K;/T;G:URZ7HO_`)S/5V:N.&<G
M1RM+>7R]/+T9>'1I\.G+LR^X_P#_V@`(`0$#`3\ASD5VU8*&B]@?%P[ZW+J`
MG@@_(YP,<3SRXQXV&79=D`\+U'0"O6=#`N>QA&CN<K$_I@3Q7NC(N`WZ&@_8
MA<+D]U`W"N:PW8B<'C1;US+8@*<TC3+\+(K^QR-5B@V@O@,UI8+5KL*<5,$@
M5-)LF)NE'BL&;KM8"UL\Q2A.W6U>G[6V7DU/_?>G^M\&\Z;@>&!A&3"V\H!)
M5=9[0^;+:WX(X[`RVI`01Q8>5^2NW)Q;TM"N"HT&L6TP90TF([H%)6K64Q:"
MN'8C(8I5VD`3$2V!;_[;VY#26[T*QY"<X0D:(+[NO]F>&;O#'A/LZ)GV$0CE
M^[A'S`)X+$\Q-6^K@F_*=,MCY`=NP%!'"X6M>R/QR-YK%0M^0,'HCX&&OX!(
MA,NX'(!]S"T\-):>OX^(+;!U*>7W0$:'G(Y4#WQ(!S-JL$,$[T#=?P5'MA4H
M"]N$O!3(#_`'.#TNV?;KU[QS@(7VN!3YS6=^WQ\W$`4W@V=NY#1T7+K(*-F$
M:CP9<RH=F12O\S1C-!!,0=PC\KK4^]##E#!0PM/B`%MJS,"WA$=E(@#K-*&L
MPLO`07SG>(/(F-/8:[IQ/X9P]JG84"/8Q_S:L($MOUPL.S`H&T[GX</0$M&0
M.-J8XNO#FMEO+2OMCL`)P2$C@J#M#FYF-O=KTC0@@#7\N33='FY*>/3:V+C9
M6U`%7<QC,O.)$QI9K;1+4$R)R5)I.[2?TLF;68'Y,U5-CI_)4:IB%<=YZ[<)
M._>+G6U2$,'!@5]UP%+KE-8`>4:VF.@2,*SEU&%-%$.10:FZ7[&!!3$Y,>TT
MR;'G^*^>]>2\>'8YS_AZ#`2!J,;"&0I:86T0][)@>OHY^6OSO+1S5;DV%>^&
M'2!SGN*K02ZHX%K'R]`C*6X/3!AJO`Z40P05N`LF6#%C9!.1YAV:F!4>5$6)
M`P-"*YR4>;L/.%ZX>8]11GJ0K-3US,XL+[X-<9O3E%:T7G;HB6&XA],XY$<.
M_P"./Y\!I?``O<%1@ZC&$<%HS%$PA*84Y7;AO.XH.?2V!8FO1?-#<;V@28D1
M*BM]N4<9$JZ(CLS>%>C50F!2;UH2%$?1:B0#ITWE3;#3+-O&QM9;H451<YKA
M_3Q-:\TU7CC,W:'&@F/R`A[,D$%M1[["]R@'>0Y-VX1NAH-W@]']=0G\?U6]
MYIZS[[^U<_VY_P#I:-^SM9]64+_T!/;/^:[+[=]$]#__V@`(`0(#`3\ASI8(
M='E>`]W-9653[[7]#-`I[S\!?O*"?"#]1DGBX7?L?PF-0V:XOMY?SKP^AT0"
M]CRO@#;DSX-.9K3LOCV]=X"=F#V89_8\\1!AX?R<C]\][!H'R4GXP1A>1+7V
M#\$ZN)H%4;QI;P=CA^L0I-%]!8=8_(,`_=AO,,3X+X=Z-Y\8UW0\)NV_['XX
M"4FX),[YC\:P+XYC]A#^^4%6Y/80=<\L27`"$`.@/=7T/&20]^O[_?!]L6E%
M_-9_.;.'LX`^("+PANWE[]"SOG`\@*=MN?/TA^A39[F;S"O4ZBZKY>7T5D;/
M?DQ<ND^!W_6(4[XGN_\`3Z5.S)3P]OY:88MC1X_>F?)1R?:!/G3\?E\)@K?W
MIYALL\GW!UAP@+M%?@5?T>4R4%*7>M/#Z(3\M^/Q'\&^V:,;ZW1![UH=FG`5
M.]V(/::;F)7O7X#*B?O^PGPX+CXH/@??AOC&HO>X\-O>*#7';#KKB:8^-7_Y
MZ(/8R-B.);CY?(9Y&:/PIJ^T]V?0"Y/PBOG.4O;G[;_7`:+Y+JZK2^*?&0RK
M@?T$.VST'H^D[_[G?C_8?H+AJ=[_`._HSVS_``)]<UFWOMN\WW]_0__:``@!
M`P,!/R'.S@3RO@Y3H-X[L&?M`?`C^,_S>R<DGXR)M.:_VN4\_P#@="_,>V#$
MT[?;Y>`?$'8]#OH(^5Z#M-!E:%=N/M)U#:Z.7K"KKZ^\T_;/"=XHM9Q1W.-]
ML]O[%.],C]T,7['"!/N+WS7<Q3Y*6.%`]R/VIM*(J#GSZ!/T*G2E+Z4\U/X/
MY9PO)MVCO-&B=8!PT7[CV<R!3N5)O24_+YQHMNR'O?V"7(#^\?N5NU./AO*E
M,W50U5?8#X/0G8AT=]$>)B%WVL&`>2%$_IF\307R].:0/),`D6%V7H(L7"H[
MA)FO1ZI/*6B:HZ\9H8YB0[05CP-'HH\2D>-9_62SSKRB?Y^V(B\C[?Y+W]+H
M!.7D9/PUB0%[?\@:'BC+D=K2-AY#VM%M@J>B"A>`UMY?9&\>3K-"!\``_+X'
M!U(&,;$Y/D]$O^GX"7G\`>W-BG-IN&>3M/'LX8>S7H*-0;$T2%K2L]D4WNV+
MMZ$]X'I?'GV0)\'E@`MN]QX+`YHKOIR4S6"4\[!GCR;->B<*J6`78T+NG+&-
M,@1;YO++^&G>:-/_`'"?=/BQ:WW;^"/V<9XHM%\&TZ4'FYWR2VGVK2:ZKLP]
M'W;7Z-C/Z\_]66S]%]=F>_L^>^L[SVP:G$ZDU/0__]H`#`,!``(1`Q$``!`!
M%[@```````6I)/@``````#N7%P```````,+[P0"2`0"`!V"`2`2``2"`=MJ"
M0222``2!CQW````````!1'X`````````+,````````?_V@`(`0$#`3\0R"?%
M>N$,R0%@$%<]&?L`(FC8H&O.E=,O4Q#;=F\HYD4<T+D>#)P0'K^P=DP%&J;9
M67!H$Z->09*KT#Y.0<WQ:P!%0@MD31[KKKOAIQ,%4XJJ4&.:)96Y_P#+F!7:
MHW2(/`VN+]*S.-*NL24W_6/F$^*$LU:8Z][<F6J.)WK%=,BOR1_08<5R"NA)
M='2@W6#K)4IQOL=!L5KJV@/I!',(HF6NPD_1,X$J6-"89/=*[R$VQ*)D,/>&
M:SV[S-3"\<A=5+=Q$3'/PWY3K(6O/#_W"'4BN)AP/RP;HF;_``8VF(A(9-M`
M/_IT3A#!?(:(/@'TGXG-%!:JPAW5%G0I08V"3AP=0F4`V5MH@1R*^'K0H]<Y
M@CP6@2@>0H'(_A&]IW!U(A<"#$G*M1SHF#6<I#L7:U+I"3`A0#R8ZN(8)+V#
M*V`".A[WA';TL1.Q\R*0`[M&,$B(@D<!,2"]RRR:A[/S&"'>-R0V>#Y/RD($
M5YM8T%7=,8<82"V`U]_+2"0"@8(-YT-RI)5&6`Z2SJ=12%@5"%:E'I<"*/&/
M[600AJ1$WRX>FL6+D(8J*7Y8#HCC0SE5*T*/#C&LRKY"9Q8UP31H-`=?PAYX
MPTPIE)-AB`99>B4(C.%E%')LZ<*DBOCBK`0:Z\<@,H5HSFI.US1Y4M%VFR0F
MY2Q``_E.QE?]8H6Z@A5#V24:$P_Z2-J59(JM8PXU#4'\!LIN(BJKI0+TT<8%
M\R547XRDZ)_)MZ?'C0$67#1LPD5&T:5P5$TJ*6>F^4::A`O(P1</XZM.:#>U
M>77`+BLB3=F)@,G'VG?9H-8#_`O)IZA2*4TLR=:8E!ZK5T'`F/3]%0K$62($
M0Z!NSX__`!P@(%_SQXGH=#2Y;#?K)WH)4FO4/%H(]Y`+0894R0+NZ5OLX+;A
M%*`^N$M*@#"PH5V_J*4$2-+`2V>%+%C2K2P/3K$XU=@K:X)A]2@V3<MHRT2H
MO7.1E6-T98YS\(7;"`,4K81UC`,1_<4AG0X(CL+6P:(`K_)S&;R_R9RM(EUP
M\TRRIGJQ7!R085FL(6\)&F+`JF!_`10-DQ<2UV:%DCFJ#$J/0CS,9>G\3><,
M+FB;\$)WDAB<:(WJ-9*/TGP`-UB1)1)+!%.(QO(Z@DC0N.77H3:F(&^3(OQ`
MN1^B]C?WQ\+_`-,8^DJKX!XEN/@6?4#.WSN9]1@4.U^W8^OMN_ZXYKT/_]H`
M"`$"`P$_$,^%F1V.@^T`XY0PFCY!L&T/(^TF/UW*_GVN_+>5&Z<J7C]HJ!WD
M)VIKW94LWQ>:$UCT30-B\&U'!LW2NO0Z9B+H#:^F4\&A8-VR@.@.':%$(*X+
MPH!3NQI7I'WF@:*B*G47M-L>5QK$=D18J?D">YWE!IWP'N)>&+R&">R5VA1'
MB<C2T02=4AX%T?;CT!N#+Z?(40C.%>+G3*OE;$V-($`]XCR82L^`+1;/(W(H
MMX^A"V8^#B##"9\TW[:EDI0BEF:/U4A,`4K>B+4&EC)(/E-$5#E55?0H$4+\
MO*A*VO=KFX@)[_?*<*C=\>VKSN+]0`Z\(ETABI*+H@HEG8XBZ&3DV:H#@RFX
M@\4,NR2@,J`>Z:G+Q/0NG&`TVD\TKG'4*=]D=<_A>L*DE56(3SI?<3:>E7V/
M7*5!PP4-'>LY%(L3X>89VK-+BZI<[$KK$>7:L9S=5MI'E12,)WS98#':"(>&
MJ?<#H;Q)/`0UP%Y$V/#UZ*N(#9S$^1;Q*@G'$D@;,00E0((*40,I2-5UC#4=
M8OE(X*#,&@H('8.%,.F4MEQWRXIYD7$=X``*-9X9)H[#SO<:0&E"EB6JC$3T
M1<VJ=,(%<!"<`-R96LF\=#<1!9!'&;%-*$N:A$XB)Y8']M@5\-T>&!.KF@%<
M"]&9\@784:R5C=`*C>HJFQ&HOH_^E3;OU])UF\\C_E_B?T9_BWI^4YF_MGO)
M</&OASGLOOGN[<_)O;>W-W>?0__:``@!`P,!/Q#-:C:V*@[(TU<R"A!&N3?2
M!6="\K"8BL+X'QX&F^,O*3B@<^S<`*]931XD(:8=$T[FU;Q()V5JX"!Y8!LF
M_0\`.S;F:RB><U0%(TSK0FBFIAWK#,N,5TXT@@=_85"6NA?+8.):`?`:PW7]
M(<T"O]J&KUD><:Y/:RX4N"#<@`4,0"H$X)'881G8/"@VSJN_0(C#?B:%C:AE
M'E,.;GYA2\4]$AC`7>"ZY[#01``C43"IZ1=H4+FJ=-HKDF!!GG#Q%%(0RN;`
M8$(%0$=.SA"(Y4LF`+;*`&@`#F^@2`930I);"!.D\3-H(,R'@AU8;:`A%[<D
MT7PRH>/(XC?#<\$$$RAH.V`64U^1OT2*+HG(Y]:)!L0VP-T55]".R;K<:O",
M=><U]5*`&N>]@[6N<5#H32B%94*=>`O'I18MQP3.\ATK5ZV9P&3R+=WD2!#`
M4,!8Q#4E$I48Q.,")!I$,*2K%C+K,KH[87O(B>RG:)BH!L0TD18FD=CI/10`
MQ)>#GAA/2!`P4ZJ.@P-8`91L+'9"62?D1)+!0EFTW=4%2!2KR(DQ*(,WUOA8
M1I<.8];T1,/RAZ-"5\*!`+(`L)5)!%"^A2DX>QEHABI%5@Q/4Y=O>I5"H:K<
M:C(Q6<0>WE0%='"^2Q;8\L.G(*/#,V/`WGV*1O:M0"Y<\&[P)"$[H@V7HS_C
M56I^CZ[=7-;TC_J?F?=WG^SWN_:N+K[S/R^CE3S;QU3VSV*>/C^R))J<>A__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```#RP``"7(```O,```.(/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`%P)-`P$1
M``(1`0,1`?_$`+@``0`#`0`#`0$````````````&!P@%`0(#!`D!`0``````
M```````````````0``$$`P`"``8#```````````!`P45`@0&$!$@0%!P$A83
M%`<1``$"!0,#`@0%`P4```````(!`P`1!`4U$M.4$"$3,4$B,B,446%Q)!4@
M0`90@F-$%A(!````````````````````<!,!`0$``P$``04!`0$``````1$A
M`!`Q05`@0'!1<6&1L?_:``P#`0`"$0,1```!_OX````````5X4\:D!A0W0>Y
MEHTV?J,Z%Y'9*'++):`#+!<)8Q1Y,2?E0%CG8*G/):YPS/YIP&6S4@,H&KP`
M```````````````"/G[3I@I@N4]BM"Q3[%?DN.D0LZIWP`5X=PDY#3IG?(J?
M4DI&#T)410X)9(*L+3!5Q:(````````(2?,`````````````````````````
M``````````'D_]H`"`$!``$%`OD>L<<:YSEL'[3PP[GL.)[]'4_BYUK&*8,G
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MVI__V@`(`0(``04"^[W_V@`(`0,``04"^[W_V@`(`0("!C\"7O_:``@!`P(&
M/P)>_]H`"`$!`08_`O[&[N-&3;@TA:3`E$A74*=B3ND6URV-7!NW+:$6\G5)
M4#2OUQ#,#I_N5^-S5[AVEUJQI'ZM?\G=_P`D?"WN>=X1^R9>F\+A&24RL@$Y
MC\T)J^:23EZ3]Y=+=3O,7&LICM3A'1VUPQ?,D<=TF*"ZU\GOW](9`4(1!IL1
M$UF:((HB(:JJJI(GKTM]76L5M5_CC++OWK5`Z39LU)+\%2]XR`R`!E+O**1V
MC-7:4Z=I6'"4B(FM":5-3^)3EZS[SZ6U]&:JKLU.\XY>*6B<)M\V]*>,U4%$
MU:;[JLHHG;:;CE$K4F5>(S>1!)44'5<53U@7;O\`TLA=W:C^,;L;KRMM'4(@
MU/E<%IP4IU14.?NO;\8HTNAD=0NL@4S1QW[8B4J9'7!54)SQ*G0B;,P+[VC2
M8$HE)36:322]X_;T=PHA-TB)FY&1OJ>D$5Q-3KWTCEV[]+B;9D!)]O(@)1)/
MW#?HJ=XH57NJT=,JK^/T0Z7,VS)LT!F1BJBJ?N&O=.\:VJ.XTA/)3D[_`"!D
M?W!^`5\]/J==DP6K\OTZ5E<Y\M+3NO?JH"JB/^XNT5%NK*G[@[E;Z6]MJKOD
M\;KL_NJ=/B+3HU)V_+J[_P"C"O&JJKA.QUXON);R8^5FDT`2-IZ]T5%[^O6Y
ML5--=*UH`MI-!0.N"-*:BQ]=]!>:1&$]_7_1*NW.F;;=6TK1&W+6**J+,=4T
MGVBFI`(C&F8;8$BEJ)&@0$59=IK+J0!5U3;Z7<[S3U@^/S4S[BIK;#X=*M%+
MWA)K-9=U])K^,NC%V9N57;ZNGIBI0*G%@O@,B4E^LV:375``1JX0@(DX4M1J
MB24RTR29+WZ>-;K74=*;2L5-)3>+Q5#:EJ75K`B$E])I[0Q1TPZ&*9H6FAG.
M0@DDFONJ]`;:NE;;@TN-O#2^*50VZB(0GY`)45$3LJ?C#%OI$)&*<9#J749*
MJJ1F:^Y$2S_I*XU)N%KMCUK<IOA\1LO*2J<Y:T-)]H9MZ5+U6%/,6G']/D%J
M<P;501-2-^B?ET6@>>=8#S-/>1K2IZFEFB?&BI)85I^OJ+@6O4+M0+(F`Z11
M&T1D&QTI+]>C]N><<:;?T:C:TZT\9BYVU(J=U&/`[7U%>B:?&=0+(DTV((`M
M#X0!%%)>_?I46UYPVFZE!0C;TZTTF)]M2*G?3"L.7"IKQ1&Q9^X!@?`VV&A&
MP\+8322>\^A4#KSK++CC)N^+3J<!IQ'/"NI%^`U'O%ON=$"6]VA\HJW2---M
M50.CI47T09K)/?UZL5]?<ZZN;I*DZNCHGE:2GIWB6:2T`AF+?LB]:F\TUUK:
M)^K%@'VV0IB;-MA`1&_JM&4BT=_[,A_B+T6DE'4-$BB4EE,5\W<5C#WS@IO1
MA[YP4WHP]\X*;T8>^<%-Z,/?."F]&'OG!3>C#WS@IO1A[YP4WHP]\X*;T8>^
M<%-Z,/?."F]&'OG!3>C#WS@IO1A[YP4WHP]\X*;T8>^<%-Z,/?."F]&'OG!3
M>C#WS@IO1A[YP4WHP]\X*;T8>^<%-Z,/?."F]&'OG!3>C#WS@IO1A[YP4WHP
M]\X*;T8>^<%-Z,/?."F]&'OG!3>C#WS@IO1A[YP4WHP]\X*;T8>^<%-Z,/?.
M"F]&'OG!3>C#WS@IO1A[YP4WHP]\X*;T8>^<%-Z,/?."F]&'OG!3>C#WS@IO
M1A[YP4WHP]\X*;T8>^<%-Z,/?."F]&'OG!3>C#WS@IO1A[YP4WHP]\X*;T8>
M^<%-Z,/?."F]&'OG!3>C#WS@IO1A[YP4WHP]\X*;T8>^<%-Z,/?."F]&'OG!
M3>C#WS@IO1A[YP4WHP]\X*;T8>^<%-Z,/?."F]&'OG!3>C#WS@IO1A[YP4WH
MP]\X*;T8>^<%-Z,/?."F]&'OG!3>C#WOV_Z(^\_^;VE'_]H`"`$!`P$_(?V*
MK]WF5,$CR"1B:M0KMV_\=P2DI8A[WH\`3GOAT<*=5LO0U$F!]2CW/A>]$@WP
M$B5KT-GQCB$4+P!'1]DYC68LI'^Q>I]QF?YTDB`?9Z5AP6(](ZZ?/9^FU#EX
M,5.0]L\<)D1UCC'6-<AUIR6V"%\'/3FTJ4L`&1]PZ]>'$0VL%.,H4(:I95=5
M>G4",G"C@QY0:):%VN*DWT18'M_^J4Q_UY'_`$9EH`2^2=@=1IJ##9":28]>
MCL+,+V\!_P"V?A"HH<X@!_J'/,*:8@Q!N9V@%K$MGC,:!6<("$")`;#"O0&A
M7\9Q*9\X$C42/``FJ`5ZF)R"U5BMM-S.46IB0E'?<OU>APJXB64!"!*XTM#9
MCHE.L#<S].81ANK)I^3!!Y/DS^X"$31W!\Z4$(TBYJ8[G$/)4Z2F:ZFGWK%.
M]**1Y(<\Y2706F@<+M4^]$ZY]"?.RG3SEB;-(6Y<*VSI,Z3LZ4@)C9Q!;8(&
M\T&!]=WZ;.%ZQD,P`;W9$+%/`'O#=S]G]WDEUB,%'^OPU.G3ITZ=.G3ITZ=.
MG3ITZ=.G3ITZ=.G3ITZ=.G3ITZ=/\'3ITZ=.G3ITZ=.G3ITZ=.G3ITZ=.G3I
MTZ=.G3ITZ=/!?%$T?H'SZ?Z<_]H`"`$"`P$_(?Y>_]H`"`$#`P$_(?Y>_]H`
M#`,!``(1`Q$``!```````````""``"``"`0"`"````0`````````````````
M2`````"``"0`"`""0"``````````"2222222222222222222222222222222
M222223__V@`(`0$#`3\0_8IRXX8&5.43%XETYZM-+_T;/[=2KL]VO!][EE!P
M@@A%0#)@[@[.I)<:X8L0:D?9.#@4Q]!*J`*JN])8)U04!)HP4'!6R,\6J,">
M'I>FT)P1#`8`@6$Y1U'XEK8M69%"_H%TQ@"607AFSB,;@=T@*!Q(J/39<V=O
M1F4L7B"";"/9.@)BL]("?[JB!1&.C.-_($[7%!5=7IJPJ].`&@QT7CK91^I=
MG95Z)T%@,B$A99)]$YBDWT;91]V#8=OF+1=9QO#D.>[:$7H9<2KW*?X1,*S*
MDS0DT-X1A'P<J24@%>=T2CS]?90G$KG/!\T2#Y#6&%G3*)UL!29?@`F\?7)1
M_P"OD24@$.A0KE7)QC00I%J.FM&J\I*]4_>@LRN5"H84<V\S/GZ+E7M`,``'
MZ"BZ(]D4"U`0IR9-6[6.IALD8.B#/!RF6^DK,Y9B$O)J4BE+42<3^CB,UC`T
M6F;QYF"WJ^=H9*NKC8S&T'$J:?O$5^.S\)(T/KWH_2UL`P=K&4'>7,#^:E#$
M3Z+#NF2B,&%,2Z0!'I_[-@R1%(!51G[.;$0>-#WA(J&'X;__`/\`_P#_`/\`
M_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_
M`/\`_P#_`/\`X/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_
M`/\`_P#_`/\`_P#_`/\`_P#_`/\`_P#_`/XT_L<,_JX5\?[.?__:``@!`@,!
2/Q#^7O_:``@!`P,!/Q#^7O_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
